Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Medicus Pharma Ltd ( (MDCX) ) just unveiled an update.
Medicus Pharma Ltd. has completed enrollment of 90 patients for its Phase 2 clinical study (SKNJCT-003) aimed at non-invasively treating basal cell carcinoma (BCC) of the skin using Doxorubicin Microneedle Array (D-MNA). The company anticipates releasing topline results in Q1 2026 and plans to request an end-of-phase 2 meeting with the FDA in H1 2026. This development represents a significant step towards offering a non-invasive, cost-effective treatment for BCC, a market opportunity estimated at $2 billion. The study is being conducted across nine clinical sites in the U.S., and the company has also received regulatory approvals to expand the study in the UK.
The most recent analyst rating on (MDCX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Underperform.
Medicus Pharma Ltd’s financial difficulties, characterized by the absence of revenue and consistent losses, are the most significant concerns. While technical indicators show some positive momentum, the negative valuation metrics underscore investor caution about long-term profitability.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd. is a biotech/life sciences company focused on advancing clinical development programs for novel and potentially disruptive therapeutic assets.
Average Trading Volume: 358,303
Technical Sentiment Signal: Sell
Current Market Cap: $41.64M
See more insights into MDCX stock on TipRanks’ Stock Analysis page.